Metformin resistance alleles in polycystic ovary syndrome: Pattern and association with glucose metabolism

Pharmacogenomics

Volumn 15, Issue 3, 2014, Pages 305-317

  Schweighofer, Natascha ^a   Lerchbaum, Elisabeth ^a   Trummer, Olivia ^a   Schwetz, Verena ^a   Pieber, Thomas ^a   Obermayer Pietsch, Barbara ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ATM; C peptide; metformin resistance; organic cation transporters; polycystic ovary syndrome; SNPs

Indexed keywords

ADULT; ATAXIA TELANGIECTASIA MUTATED PROTEINS; C-PEPTIDE; DRUG RESISTANCE; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84894411100     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.223     Document Type: Article

References (56)

1. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum. Reprod. Update 11(6), 631-643 (2005).
2. El-Mir MY, Nogueira V, Fontaine E et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275(1), 223-228 (2000).
3. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3), 607-614 (2000).
4. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann. Intern. Med. 137(1), 25-33 (2002).
5. Foretz M, Hebrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120(7), 2355-2369 (2010).
6. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001).
7. Palomba S, Falbo A, Zullo F et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30(1), 1-50 (2009).
8. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol. 154(6), 763-775 (2006).
9. Morin-Papunen L, Rantala AS, Unkila-Kallio L et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97(5), 1492-1500 (2012).
10. van Leeuwen N, Nijpels G, Becker ML et al. A gene variant near ATM is significantly associated with metformin treatment response in Type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 55(7), 1971-1977 (2012).
11. Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans. 39(1), 1-13 (2011).
12. Wang DS, Jonker JW, Kato Y et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302(2), 510-515 (2002).
13. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 90(4), 397-421 (2001).
14. Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann. Med. 44(2), 119-129 (2012).
15. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J. Clin. Invest. 117(5), 1226-1229 (2007).
16. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117(5), 1422-1431 (2007).
17. Tzvetkov MV, Vormfelde SV, Balen D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86(3), 299-306 (2009).
18. Shu Y, Brown C, Castro RA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2), 273-280 (2008).
19. Chen L, Takizawa M, Chen E et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J. Pharmacol. Exp. Ther. 335(1), 42-50 (2010).
20. Shikata E, Yamamoto R, Takane H et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 52(2), 117-122 (2007).
21. Jablonski KA, McAteer JB, de Bakker PI et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59(10), 2672-2681 (2010).
22. Song IS, Shin HJ, Shim EJ et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84(5), 559-562 (2008).
23. Song IS, Shin HJ, Shin JG. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 38(9), 1252-1262 (2008).
24. Faria A, Monteiro R, Pestana D et al. Impact of culture media glucose levels on the intestinal uptake of organic cations. Cytotechnology 62(1), 23-29 (2010).
25. Grover B, Buckley D, Buckley AR et al. Reduced expression of organic cation transporters rOct1 and rOct2 in experimental diabetes. J. Pharmacol. Exp. Ther. 308(3), 949-956 (2004).
26. Nowicki MT, Aleksunes LM, Sawant SP et al. Renal and hepatic transporter expression in Type 2 diabetic rats. Drug Metab. Lett. 2(1), 11-17 (2008).
27. Yacovino LL, Aleksunes LM. Endocrine and metabolic regulation of renal drug transporters. J. Biochem. Mol. Toxicol. 26(10), 407-421 (2012).
28. Jang EH, Kim HK, Park CS et al. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab. Pharmacokinet. 25(4), 392-397 (2010).
29. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41-47 (2004).
30. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31(Suppl. 1), S12-S54 (2008).
31. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K et al. Common variants near ATM are associated with glycemic response to metformin in Type 2 diabetes. Nat. Genet. 43(2), 117-120 (2011).
32. Zhang Y, Wang Y, Bao C et al. Metformin interacts with AMPK through binding to gamma subunit. Mol. Cell. Biochem. 368(1-2), 69-76 (2012).
33. Diamanti-Kandarakis E, Christakou CD, Kandaraki E et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 162(2), 193-212 (2010).
34. Harborne L, Fleming R, Lyall H et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 361(9372), 1894-1901 (2003).
35. Barba M, Schunemann HJ, Sperati F et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin. Endocrinol. (Oxf.) 70(5), 661-670 (2009).
36. Rice S, Pellatt L, Ramanathan K et al. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology 150(10), 4794-4801 (2009).
37. Gambineri A, Tomassoni F, Gasparini DI et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95(10), E204-E208 (2010).
38. Florez JC, Jablonski KA, Taylor A et al. The C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention program. Diabetes Care 35(9), 1864-1867 (2012).
39. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N. Engl. J. Med. 282(25), 1396-1402 (1970).
40. Bar RS, Levis WR, Rechler MM et al. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N. Engl. J. Med. 298(21), 1164-1171 (1978).
41. Sun Y, Connors KE, Yang DQ. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol. Cell. Biochem. 306(1-2), 239-245 (2007).
42. Fu X, Wan S, Lyu YL et al. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS ONE 3(4), e2009 (2008).
43. Sanli T, Rashid A, Liu C et al. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 221-229 (2010).
44. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 60(1), 168-176 (2011).
45. Stocker SL, Morrissey KM, Yee SW et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin. Pharmacol. Ther. 93(2), 186-194 (2013).
46. Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda) 21, 48-60 (2006).
47. Legro RS, Barnhart HX, Schlaff WD et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 93(3), 792-800 (2008).
48. López-Bermejo A, Díaz M, Morán E et al. A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. Diabetes Care 33(7), 1544-1548 (2010).
49. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J. Biol. Chem. 276(39), 36383-36390 (2001).
50. Ferk P, Teran N, Gersak K. The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum. Reprod. 22(4), 1031-1036 (2007).
51. Xita N, Tsatsoulis A, Chatzikyriakidou A et al. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J. Clin. Endocrinol. Metab. 88(12), 5976-5980 (2003).
52. Ibáñez L, Ong KK, Mongan N et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 88(7), 3333-3338 (2003).
53. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87(1), 161-165 (2002).
54. Krithivas K, Yurgalevitch SM, Mohr BA et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J. Endocrinol. 162(1), 137-142 (1999).
55. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21, 1440-1447 (1961).
56. Díaz M, Lopez-Bermejo A, Petry CJ et al. Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms. Fertil. Steril. 94(7), 2800-2803.e1 (2010).